On October 6, Provention announced an agreement with Sanofi to jointly advance the commercialization of teplizumab. Previously, the FDA has accepted a Biologics License Application
The University of Queensland in Australia has announced that a new study has revealed how COVID-19 affects the heart and how it differs from that
On October 4, miRecule announced that it has entered into a strategic cooperation and exclusive license agreement with Sanofi to accelerate the development of “best-in-class”
On October 4, Pfizer announced that the oral PARP inhibitor Talzenna (talazoparib) combined with Xtandi (enzalutamide) in the treatment of male patients with metastatic castration-resistant
On October 3, Alexion, a subsidiary of AstraZeneca’s rare disease business, announced that it had reached a definitive acquisition agreement with Lexington. The acquisition is
On October 3, Incyte announced the acquisition of Villaris Therapeutics, which was invested and incubated by Medicxi, and acquired the latter’s anti-IL-15Rβ monoclonal antibody drug
On September 30, Intercept announced that the phase III REVERSE study of obeticholic acid (Ocaliva, obeticholic acid, OCA) in the treatment of nonalcoholic steatohepatitis (NASH)-related
On October 1, Taiho Oncology announced that the FDA has approved the marketing authorization application for the FGFR inhibitor futibatinib for the treatment of patients
Tumor immunology is a science that studies the relationship between tumor antigens, immune function of the body, and the occurrence, development and prognosis of tumors;
Recently, the FDA has rejected a number of products, one of which is a PDC drug that it has written in the past. In the
On September 29, the CDE official website showed that the marketing application for ibandronate sodium tablets (Bonviva) has been accepted. Ibandronate sodium is an anti-osteoporosis
On September 27, Exicure announced plans to restructure the company and integrate resources to continue exploring strategic alternatives to maximize shareholder value. Exicure will cut
